インフルエンザ治療薬市場：薬剤クラス別、デリバリー形態別、インフルエンザタイプ別、流通チャネル別、エンドユーザー別-2025～2030年の世界予測

インフルエンザ治療薬市場は、2023年に34億4,000万米ドルと評価され、2024年には36億米ドルに達すると予測され、CAGR 5.00%で成長し、2030年には48億4,000万米ドルに達すると予測されています。

インフルエンザ治療薬市場は、インフルエンザの症状を予防、軽減、治療するために使用される物質によって定義され、抗ウイルス薬や様々な支持療法が含まれます。これらの薬剤の必要性は、インフルエンザの季節的流行と潜在的な重症化から生じ、公衆衛生上の重大な課題となっています。用途は、個々の予防対策からヘルスケア機関が採用する広範な公衆衛生戦略まで多岐にわたる。最終用途には、病院、薬局、オンラインドラッグストアなどが含まれ、処方薬と市販薬の両方のニーズに対応しています。市場成長に影響を与える主な要因としては、インフルエンザ予防に対する世界の意識の高まり、薬剤製剤の進歩、政府による健康への取り組みの拡大などが挙げられます。現在アクセスが制限されている新興国市場に進出する可能性や、吸入器や速効性製剤のようなより効率的な送達メカニズムの開発にもチャンスがあります。しかし、ジェネリック医薬品との競合、規制状況の厳しさ、ワクチンへの二の足といった限界や課題が、市場の成長を制限する可能性があります。ワクチン技術、特に万能インフルエンザワクチンの開発や個別化医療アプローチにおける絶え間ない技術革新は、成長のための有望な手段を提供します。さらに、AIを活用したインフルエンザ予測モデルなどのデジタル技術の統合は、流通戦略と市場への浸透効率を高めることができます。これらのイノベーションは、進化する健康ニーズに対応する消費者中心のソリューションを提供する可能性があります。さらに、経済的圧力は消費者の購買力に影響を与える可能性があり、費用対効果の高い代替品とアクセス戦略の重要性が浮き彫りになります。市場は競合が激しく、大手製薬会社が優位を占めているが、斬新で効率的なソリューションを提供できる新規参入の余地もあります。人口動態特有のニーズに合わせて製品を調整し、教育キャンペーンを通じて認知度を拡大すれば、競争優位に立てる可能性があります。成長を目指す企業にとって、ヘルスケアプロバイダーとの連携に注力し、市場インサイトと予測のためにAIを活用することは、このダイナミックな市場環境の中でナビゲートし、繁栄する上で大きなメリットをもたらすと思われます。

市場力学：急速に進化するインフルエンザ治療薬市場の主要市場インサイトを公開

インフルエンザ治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界のインフルエンザの流行拡大
  • インフルエンザ管理に対する政府の取り組みと啓発プログラム
  • 個別化医療への志向の高まり
• 市場抑制要因
  • 新型インフルエンザ治療薬の開発コストの高騰
• 市場機会
  • 規制当局によるインフルエンザ治療薬承認の急増
  • 新しい製剤や送達方法の開発に対する有利な投資
• 市場の課題
  • インフルエンザ治療薬による健康への悪影響

ポーターの5つの力：インフルエンザ治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：インフルエンザ治療薬市場における外部からの影響の把握

外部マクロ環境要因は、インフルエンザ治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析インフルエンザ治療薬市場における競合情勢の把握

インフルエンザ治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスインフルエンザ治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、インフルエンザ治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨インフルエンザ治療薬市場における成功への道筋を描く

インフルエンザ治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中でインフルエンザの蔓延が増加
    • インフルエンザ管理に関する政府の取り組みと啓発プログラム
    • 個別化医療へのアプローチへの傾向の高まり
  • 抑制要因
    • 新型インフルエンザ治療薬開発に伴う高額な費用
  • 機会
    • 規制当局によるインフルエンザ治療薬の承認急増
    • 新しい処方と投与方法の開発に対する有利な投資
  • 課題
    • インフルエンザ治療薬による健康への悪影響
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 インフルエンザ治療薬市場薬剤クラス別

• バロキサビル
• オセルタミビル
• ペラミビル
• ザナミビル

第7章 インフルエンザ治療薬市場配送形態別

• 吸入器
• 静脈内
• 液体/シロップ
• 錠剤/カプセル

第8章 インフルエンザ治療薬市場インフルエンザの種類別

• タイプA
• タイプB
• タイプC
• タイプD

第9章 インフルエンザ治療薬市場：流通チャネル別

• オフライン
• オンライン

第10章 インフルエンザ治療薬市場：エンドユーザー別

• 外来手術センター
• 在宅ケア施設
• 病院・クリニック

第11章 南北アメリカのインフルエンザ治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域のインフルエンザ治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカのインフルエンザ治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Agilent Technologies, Inc.
• AstraZeneca PLC
• Bio-Rad Laboratories, Inc.
• Bristol-Myers Squibb Company
• Cocrystal Pharma, Inc.
• CSL Limited
• Daiichi Sankyo Company, Limited
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Lupin Limited
• Merck & Co., Inc.
• NATCO Pharma Limited
• Novartis AG
• Pfizer Inc.
• Qiagen N.V.
• Sandoz International GmbH
• Sanofi SA
• Shionogi & Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Zydus Pharmaceuticals, Inc.

LIST OF FIGURES

• FIGURE 1. INFLUENZA MEDICATION MARKET RESEARCH PROCESS
• FIGURE 2. INFLUENZA MEDICATION MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL INFLUENZA MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. INFLUENZA MEDICATION MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. INFLUENZA MEDICATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. INFLUENZA MEDICATION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL INFLUENZA MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. INFLUENZA MEDICATION MARKET DYNAMICS
• TABLE 7. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY LIQUID/SYRUP, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLETS/CAPSULES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TYPE A, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TYPE B, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TYPE C, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TYPE D, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOMECARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 45. CANADA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 46. CANADA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 47. CANADA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 48. CANADA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. CANADA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. CHINA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 73. CHINA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 74. CHINA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 75. CHINA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. CHINA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. INDIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 78. INDIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 79. INDIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 80. INDIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 81. INDIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 163. ITALY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 164. ITALY INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 165. ITALY INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 166. ITALY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 167. ITALY INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 183. POLAND INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 184. POLAND INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 185. POLAND INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 186. POLAND INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 187. POLAND INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 188. QATAR INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 189. QATAR INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 190. QATAR INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 191. QATAR INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 192. QATAR INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 238. INFLUENZA MEDICATION MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 239. INFLUENZA MEDICATION MARKET, FPNV POSITIONING MATRIX, 2023

The Influenza Medication Market was valued at USD 3.44 billion in 2023, expected to reach USD 3.60 billion in 2024, and is projected to grow at a CAGR of 5.00%, to USD 4.84 billion by 2030.

The influenza medication market is defined by the substances used to prevent, reduce, or treat flu symptoms, which can include antiviral drugs and various supportive treatments. The necessity of these medications arises from the seasonal prevalence and potential severity of influenza outbreaks, which pose significant public health challenges. The application spans from individual preventive measures to broader public health strategies employed by healthcare institutions. End-use scope includes hospitals, pharmacies, and online drug stores, catering to both prescription and over-the-counter needs. Key factors influencing market growth include increasing global awareness of flu prevention, advancements in drug formulations, and growing governmental health initiatives. Opportunities arise from the potential to expand into emerging markets where access is currently limited, as well as developing more efficient delivery mechanisms like inhalers or faster-acting formulations. However, limitations and challenges such as high competition from generic drugs, stringent regulatory landscapes, and vaccine hesitancy can restrict market growth. Continuous innovation in vaccine technology, particularly in the development of universal influenza vaccines and personalized medicine approaches, offers promising avenues for growth. Additionally, digital technology integration, such as AI-driven flu prediction models, can enhance distribution strategies and market penetration efficiency. These innovations could offer consumer-centric solutions that meet the evolving health needs. Furthermore, economic pressures can affect consumer purchasing power, highlighting the importance of cost-effective alternatives and access strategies. The market is competitive, with large pharmaceutical companies dominating, but there's room for new entrants that can offer novel, efficient solutions. Tailoring products to demographic-specific needs and expanding awareness through education campaigns could provide competitive advantages. For businesses seeking growth, focusing on collaborations with healthcare providers and leveraging AI for market insight and prediction can offer significant benefits in navigating and thriving within this dynamic market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Influenza Medication Market

The Influenza Medication Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of influenza across the globe
  • Government initiatives and awareness programs for influenza management
  • Growing inclination towards personalized medicine approaches
• Market Restraints
  • Associated high cost of novel influenza drug development
• Market Opportunities
  • Surge in influenza drug approvals from regulatory authorities
  • Favorable investments for development of new formulations and delivery methods
• Market Challenges
  • Adverse health outcomes of influenza medications

Porter's Five Forces: A Strategic Tool for Navigating the Influenza Medication Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Influenza Medication Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Influenza Medication Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Influenza Medication Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Influenza Medication Market

A detailed market share analysis in the Influenza Medication Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Influenza Medication Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Influenza Medication Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Influenza Medication Market

A strategic analysis of the Influenza Medication Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Influenza Medication Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., AstraZeneca PLC, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Cocrystal Pharma, Inc., CSL Limited, Daiichi Sankyo Company, Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Lupin Limited, Merck & Co., Inc., NATCO Pharma Limited, Novartis AG, Pfizer Inc., Qiagen N.V., Sandoz International GmbH, Sanofi SA, Shionogi & Co., Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Influenza Medication Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Class, market is studied across Baloxavir, Oseltamivir, Peramivir, and Zanamivir.
• Based on Delivery Form, market is studied across Inhalers, Intravenous, Liquid/Syrup, and Tablets/Capsules.
• Based on Influenza Type, market is studied across Type A, Type B, Type C, and Type D.
• Based on Distribution Channel, market is studied across Offline and Online.
• Based on End-User, market is studied across Ambulatory Surgical Centers, Homecare Facilities, and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of influenza across the globe
    • 5.1.1.2. Government initiatives and awareness programs for influenza management
    • 5.1.1.3. Growing inclination towards personalized medicine approaches
  • 5.1.2. Restraints
    • 5.1.2.1. Associated high cost of novel influenza drug development
  • 5.1.3. Opportunities
    • 5.1.3.1. Surge in influenza drug approvals from regulatory authorities
    • 5.1.3.2. Favorable investments for development of new formulations and delivery methods
  • 5.1.4. Challenges
    • 5.1.4.1. Adverse health outcomes of influenza medications
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Influenza Medication Market, by Drug Class

• 6.1. Introduction
• 6.2. Baloxavir
• 6.3. Oseltamivir
• 6.4. Peramivir
• 6.5. Zanamivir

7. Influenza Medication Market, by Delivery Form

• 7.1. Introduction
• 7.2. Inhalers
• 7.3. Intravenous
• 7.4. Liquid/Syrup
• 7.5. Tablets/Capsules

8. Influenza Medication Market, by Influenza Type

• 8.1. Introduction
• 8.2. Type A
• 8.3. Type B
• 8.4. Type C
• 8.5. Type D

9. Influenza Medication Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Offline
• 9.3. Online

10. Influenza Medication Market, by End-User

• 10.1. Introduction
• 10.2. Ambulatory Surgical Centers
• 10.3. Homecare Facilities
• 10.4. Hospitals & Clinics

11. Americas Influenza Medication Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Influenza Medication Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Influenza Medication Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Agilent Technologies, Inc.
• 3. AstraZeneca PLC
• 4. Bio-Rad Laboratories, Inc.
• 5. Bristol-Myers Squibb Company
• 6. Cocrystal Pharma, Inc.
• 7. CSL Limited
• 8. Daiichi Sankyo Company, Limited
• 9. Eli Lilly and Company
• 10. F. Hoffmann-La Roche AG
• 11. GlaxoSmithKline PLC
• 12. Lupin Limited
• 13. Merck & Co., Inc.
• 14. NATCO Pharma Limited
• 15. Novartis AG
• 16. Pfizer Inc.
• 17. Qiagen N.V.
• 18. Sandoz International GmbH
• 19. Sanofi SA
• 20. Shionogi & Co., Ltd.
• 21. Sun Pharmaceutical Industries Ltd.
• 22. Takeda Pharmaceutical Company Limited
• 23. Teva Pharmaceutical Industries Ltd.
• 24. Viatris Inc.
• 25. Zydus Pharmaceuticals, Inc.